Previous Article | Next Article 
Molecular and Cellular Biology, August 2001, p. 5082-5093, Vol. 21, No. 15
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.15.5082-5093.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of Insulin Receptor Substrate 1 (IRS-1) and
IRS-2 as Signaling Intermediates in the
6
4
Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase
and Promotion of Invasion
Leslie M.
Shaw*
Division of Cancer Biology and Angiogenesis,
Department of Pathology, Beth Israel Deaconess Medical Center and
Harvard Medical School, Boston, Massachusetts 02215
Received 17 November 2000/Returned for modification 16 January
2001/Accepted 30 April 2001
 |
ABSTRACT |
Expression of the
6
4 integrin increases the invasive
potential of carcinoma cells by a mechanism that involves activation of
phosphoinositide 3-OH kinase (PI3K). In the present study, we
investigated the signaling pathway by which the
6
4 integrin activates PI3K. Neither the
6 nor the
4 cytoplasmic domain
contains the consensus binding motif for PI3K, pYMXM, indicating that
additional proteins are likely to be involved in the activation of this
lipid kinase by the
6
4 integrin. We identified insulin receptor
substrate 1 (IRS-1) and IRS-2 as signaling intermediates in the
activation of PI3K by the
6
4 integrin. IRS-1 and IRS-2 are
cytoplasmic adapter proteins that do not contain intrinsic kinase
activity but rather function by recruiting proteins to surface
receptors, where they organize signaling complexes. Ligation of the
6
4 receptor promotes tyrosine phosphorylation of IRS-1 and IRS-2 and increases their association with PI3K, as determined by
coimmunoprecipitation. Moreover, we identified a tyrosine residue in
the cytoplasmic domain of the
4 subunit, Y1494, that is required for
6
4-dependent phosphorylation of IRS-2 and activation of PI3K in
response to receptor ligation. Most importantly, Y1494 is essential for
the ability of the
6
4 integrin to promote carcinoma invasion.
Taken together, these results imply a key role for the IRS proteins in
the
6
4-dependent promotion of carcinoma invasion.
 |
INTRODUCTION |
Cell adhesion molecules play
an important role in normal epithelia, and changes in their expression
and function contribute to the progression of epithelial cells to
invasive, metastatic carcinoma. For example, cell-cell interactions in
many tumors are altered through a quantitative decrease in cadherin
expression, which reduces intercellular adhesion (5). This
disruption of cell-cell adhesion is permissive for increased cell
motility. Cell adhesion can also be modified through qualitative
changes in receptor function that promote the dynamic adhesion that is required for motile, invasive cells (31). In recent years,
a significant amount of evidence to suggest that the
6
4 integrin is a member of this category of adhesion receptors has accumulated. Specifically, the expression of this integrin receptor is maintained in
carcinoma cells but it functions in a manner distinct from its role in
normal epithelial cells (55). The involvement of the
4
integrin subunit in carcinoma cell biology was initially suggested by
its identification as a tumor-related antigen expressed in metastatic
cancer (22). Since then, many studies have reported a
strong association of
4 expression with solid-tumor progression. For
example, the
4 subunit is not expressed in the normal thyroid but
its expression correlates with the progression to invasive thyroid
carcinoma (62). The
4 subunit is also expressed in androgen receptor-negative invasive prostate carcinomas and at the
leading edges of invading gastric carcinomas (6, 75). Moreover, expression of the
4 subunit correlates with a poor prognosis in patients with squamous cell, breast, and colon carcinomas (23, 71, 82). These correlative data have been supported more recently by functional studies that have provided mechanistic insight into how the
6
4 integrin contributes to tumor
progression. In previous studies, we demonstrated that the
6
4
integrin can increase the invasive potential of breast carcinoma cells,
a finding that has been confirmed for other cell types as well
(12, 21, 64, 67). Furthermore, expression of the
6
4
receptor increases the survival of p53 mutant carcinoma cells (2,
74). Given that invasion and survival are two critical functions
of metastatic cells, it is important to understand in more detail the
mechanism of action of the
6
4 integrin in tumor cells.
In normal epithelia, the
6
4 integrin functions as a receptor for
the laminin family of extracellular matrix proteins and mediates the
stable attachment of epithelial cells to the underlying basement
membrane (7, 41). Many studies, including those involving
knockout of the
4 subunit, have substantiated the importance of the
adhesive contributions of the
6
4 integrin to normal epithelial function (19, 81). In the absence of the
4 subunit, and
more specifically the
4 cytoplasmic domain, a lethal blistering of the epithelium, which is known as epidermolysis bullosa, occurs (19, 81). In carcinoma cells, the
6
4 integrin also
functions as a laminin receptor and the
4 subunit interacts with the
actin cytoskeleton to promote the formation of actin-rich structures that are important for cell motility (54, 56). However, in addition to its mechanical involvement in mediating adhesive
interactions, the
6
4 integrin activates intracellular signaling
pathways that are essential for the ability of this receptor to promote
tumor progression (51, 52, 64). For example, our analysis
of the mechanism involved in the
6
4-dependent promotion of
invasion revealed that phosphoinositide 3-OH kinase (PI3K) activation
by the receptor is essential for this function (64). The
ability of the
6
4 integrin to promote PI3K activation is greater
than that observed for other
1 integrins, which supports the
increased potential of this integrin to promote carcinoma invasion.
Activation of PI3K by the
6
4 integrin is also required for the
ability of this integrin to promote carcinoma cell survival through the activation of the Akt kinase (2, 3, 74).
PI3K is a lipid kinase that phosphorylates the D3 position of
inositol lipids to form the products phosphatidylinositol (PtdIns)-3-P, PtdIns-3,4-P2, and
PtdIns-3,4,5-P3 (76). These D3
phosphoinositides are expressed at very low levels in unstimulated
cells, but their levels are increased in response to many different
stimuli, supporting their role as second messengers. A major function
of the D3 phosphoinositides is to bind and recruit signaling molecules
to the plasma membrane, where they can interact with other regulatory
and effector molecules (76). The involvement of PI3K in
carcinoma cell biology has been proposed from both direct and indirect
evidence. As mentioned above, PI3K activity promotes carcinoma invasion
and survival, and it has also been implicated in promoting
anchorage-independent growth (20, 34, 35, 64). An avian
sarcoma virus that encodes the catalytic subunit of PI3K transforms
chicken embryo fibroblasts, suggesting that PI3K can also play a role
in the early stages of tumor initiation (11). Finally,
PTEN, a lipid phosphatase that regulates the levels of the PI3K
lipid products, is frequently mutated or deleted in tumors (9,
18). The identification of the PTEN gene as a tumor
suppressor gene demonstrates the importance of tightly regulating the
activity of PI3K. In light of these findings, the relevance of
determining how the
6
4 integrin activates the PI3K signaling
pathway is evident.
The
6
4 integrin is distinct from other integrin receptors because
the
4 subunit contains a 1,000-amino-acid cytoplasmic domain
(27, 70, 72). This large intracellular domain is important
for many of the known
6
4-dependent functions. For example, the
4 cytoplasmic domain is essential for hemidesmosome formation in
normal epithelial cells and it is required for promoting carcinoma cell
invasion (44, 64). In the absence of the
4 cytoplasmic
domain, the
6
4 receptor is not capable of activating PI3K or
other signaling pathways that have been shown to be activated by this
integrin, including the mitogen-activated protein kinase (MAPK) pathway
(64). Although a number of proteins that interact with the
4 cytoplasmic domain in hemidesmosomes have been identified, very
little is known about the structural requirements for signaling by this
integrin or the specific interactions that occur with downstream
effectors to initiate signals (48, 57). Recently, the
binding site in the
4 cytoplasmic domain for the adapter protein
Shc, which recruits Grb2 and Sos to promote Ras activation, has been
identified (16, 43). However, the binding motif for the
p85 regulatory subunit of PI3K, YMXM, is not present in the
4
cytoplasmic domain, which suggests that alternative mechanisms are
required to recruit this lipid kinase (10).
In the present study, we have examined the mechanism by which the
6
4 integrin activates the PI3K signaling pathway. In light of the
fact that the
4 subunit cytoplasmic domain does not contain a
binding site to directly interact with PI3K, we sought to identify the
intermediate proteins that are responsible for recruiting PI3K to the
plasma membrane in response to
6
4 ligation. We identified two
members of the insulin receptor substrate (IRS) family, IRS-1 and
IRS-2, which are specific mediators of
6
4-dependent activation of
PI3K (84). In addition, we investigated the structural
requirements of the
4 subunit cytoplasmic domain for PI3K
activation. Through this analysis we identified a specific
tyrosine residue in the
4 subunit, Y1494, that is required for
6
4-dependent activation of PI3K and, importantly, for the ability
of this integrin receptor to promote carcinoma invasion.
 |
MATERIALS AND METHODS |
Cells and antibodies.
MDA-MB-435 cells were grown in
Dulbecco's modified Eagle's medium (DMEM; Biowhittaker) supplemented
with 10% fetal calf serum (Sigma), 1% penicillin-streptomycin
(Gibco), and 1% GlutaMax (Gibco). T47D cells were grown in DMEM
supplemented with 10% fetal calf serum, 1% penicillin-streptomycin,
1% GlutaMax, and 5 µg of insulin (Gibco)/ml. The rat monoclonal
antibody that recognizes the
6-integrin subunit (135-13C) was a gift
from Rita Falcioni, and the mouse monoclonal antibody that recognizes
the
4-integrin subunit (UM-A9) was purchased from Ancell. The
IRS-1-specific polyclonal antibody was purchased from Santa Cruz
Biotechnology. The IRS-2-specific polyclonal antibody and the 4G10
phosphotyrosine-specific monoclonal antibody were purchased from
Upstate Biotechnology Inc. The RC-20 biotinylated-phosphotyrosine-specific monoclonal antibody was purchased
from Transduction Labs. The p85-specific polyclonal antiserum was a
gift from Alex Toker.
Integrin clustering.
Cells were removed from their dishes
with trypsin and washed twice with RPMI medium containing 25 mM HEPES
(RH) and 0.1% heat inactivated bovine serum albumin (BSA; RH-BSA).
After being washed, the cells were resuspended in the same buffer at a
concentration of 2 × 106 cells/ml and
incubated for 30 min with integrin-specific antibodies or in buffer
alone. The cells were washed once, resuspended in the same
buffer, and added to plates that had been coated overnight with
anti-mouse immunoglobulin G (IgG). After a 30-min incubation at 37°C,
the cells were washed twice with cold phosphate-buffered saline (PBS)
and solubilized at 4°C for 10 min in a 20 mM Tris buffer, pH 7.4, containing 0.14 M NaCl, 1% NP-40, 10% glycerol, 1 mM sodium
orthovanadate, 2 mM phenylmethylsulfonyl fluoride, and 5 µg of
aprotinin, pepstatin, and leupeptin/ml. Nuclei were removed by
centrifugation at 12,000 × g for 10 min. For laminin attachment assays, cells were added to plates (100 mm in
diameter) that had been coated overnight with 150 µg of
laminin-1 and incubated for 45 min at 37°C.
Immunoprecipitation and immunoblotting.
Aliquots of cell
extracts containing equivalent amounts of protein were incubated for
3 h at 4°C with antibodies and protein A- or protein G-Sepharose
(Pharmacia) with constant agitation. The beads were washed three times
in the extraction buffer. Laemmli sample buffer was added to the
samples, which were then incubated at 100°C for 4 min.
Immunoprecipitates were resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
to nitrocellulose filters. The filters were blocked for 1 h using
a 50 mM Tris buffer, pH 7.5, containing 0.15 M NaCl and 0.05% Tween 20 (TBST) and 5% (wt/vol) Carnation dry milk. The filters were incubated
for 1 h in the same buffer containing primary antibodies. After
three 10-min washes in TBST, the filters were incubated for 1 h in
blocking buffer containing horseradish peroxidase (HRP)-conjugated
secondary antibodies. After three 10-min washes in TBST, proteins were
detected by enhanced chemiluminescence (Pierce). For RC-20
phosphotyrosine immunoblots, the filters were blocked for 1 h
using a 10 mM Tris buffer, pH 7.5, containing 0.5 M NaCl and 0.1%
Tween 20 (RC-20 buffer) and 2% (wt/vol) Carnation dry milk. The
filters were washed briefly in RC-20 buffer and then incubated
overnight at 4°C in RC-20 buffer containing 3% (wt/vol) BSA and a
1:500 dilution of the RC-20 antibody. After being washed, the filters
were incubated for 1 h in blocking buffer containing
HRP-conjugated streptavidin, and the proteins were detected by enhanced chemiluminescence.
PI3K kinase assay.
To assay PI3K activity, aliquots of cell
extracts that contained equivalent amounts of protein were incubated
for 3 h at 4°C with antibodies and protein A-Sepharose
(Pharmacia). The Sepharose beads were washed twice with solubilization
buffer and twice with a 10 mM HEPES buffer, pH 7, containing 0.1 mM
EGTA (kinase buffer). After removal of the last wash, the beads were
resuspended in kinase buffer containing 10 µg of sonicated crude
brain lipids (Sigma), 100 µM ATP, 25 mM MgCl2,
and 10 µCi of [
-32P]ATP and incubated for
10 min at room temperature. The reaction was stopped by the addition of
60 µl of 2 N HCl and 160 µl of a 1:1 mixture of chloroform and
methanol. Lipids were resolved by using thin-layer chromatography
plates coated with potassium oxalate.
Site-directed mutagenesis.
The cloning of the human
wild-type
4 cDNA (
4D) and its transfection into the
MDA-MB-435 cell line have been described previously (13,
64). Tyrosine residues 1257 and 1494 in the
4 subunit were
mutated to phenylalanine residues using the Quickchange site-directed mutagenesis kit (Stratagene). Briefly, overlapping primers containing the desired mutations were used to amplify the
4 cDNA and vector by
PCR and the resulting point mutations were confirmed by dideoxy sequencing. The vectors containing the mutant
4 cDNAs were
transfected into the MDA-MB-435 cell line using Lipofectamine (Gibco)
according to the manufacturer's instructions. Neomycin-resistant cells
were isolated by selective growth in medium containing G418 (0.8 mg/ml; Gibco). The stable transfectants were pooled, and subclones of cells
that expressed the mutant
4 subunits on the cell surface were
isolated by fluorescence-activated cell sorting (FACS). The human
4
integrin-specific monoclonal antibody, UM-A9 (Ancell), was used
for this sorting and for subsequent analysis of the transfectants.
Analysis of integrin surface expression.
The relative
surface expression of the
4-integrin subunit on the transfected
MDA-MB-435 subclones was assessed by flow cytometry. For this purpose,
aliquots of cells (5 × 105) were incubated
for 45 min at room temperature with RH-BSA and either the
4-specific
antibody or nonspecific mouse IgG (Sigma). The cells were washed two
times with RH-BSA and then incubated with goat anti-mouse IgG coupled
to Cy2 (Jackson Immunoresearch) for 45 min at room temperature. After
being washed two times with RH-BSA, the cells were resuspended in PBS
and analyzed by flow cytometry.
Invasion assay.
Matrigel invasion assays were performed as
described previously (63, 64) using 6.5-mm-diameter
Transwell chambers (8-µm pore size; Costar). Matrigel purified
from the Englebreth-Holm-Swarm tumor was diluted in cold distilled
water, added to the Transwells (5 µg/well), and dried in a sterile
hood. The Matrigel was then reconstituted with medium for 1 h at
37°C before the addition of cells. Cells (0.5 × 105) were resuspended in serum-free DMEM
containing 0.1% BSA, and cells were added to each well. Conditioned
NIH 3T3 medium was added to the bottom wells of the chambers. After
4 h, the cells that had not invaded were removed from the upper
faces of the filters using cotton swabs and the cells that had invaded
to the lower surfaces of the filters were fixed in methanol and then stained with a 0.2% solution of crystal violet in 2% ethanol. Invasion was quantitated by visual counting. The mean of five individual fields in the center of the filter, where invasion was the
highest, was obtained for each well.
Adhesion assays.
Adhesion assays were performed as described
previously (63). Briefly, multiwell tissue culture plates
(11.3 mm in diameter) were coated overnight at 4°C with 0.2 ml of PBS
containing either murine laminin-1 (20 µg/ml) or rat collagen I (20 µg/ml). The wells were then washed with PBS and blocked with RH-BSA.
Cells (105) were resuspended in RH-BSA and added to the
protein-coated wells. After a 60-min incubation at 37°C, the wells
were washed three times with RH at 37°C, fixed for 15 min with
methanol, and stained with a 0.2% solution of crystal violet in 2%
ethanol. The crystal violet stain was solubilized with a 1% solution
of SDS, and adhesion was quantitated by measuring the absorbance at 595 nm.
 |
RESULTS |
Identification of IRS-1 and IRS-2 as intermediates in the
activation of PI3K by the
6
4 integrin.
In previous work, we
demonstrated that ligation of the
6
4 integrin promotes
significantly more PI3K activity than ligation of the
6
1 integrin
or other
1 integrins (64). PI3K is activated by
recruitment of the p85 regulatory subunit to phosphotyrosine-containing binding motifs (pYMXM) (10). Neither the
6- nor the
4-subunit cytoplasmic domain contains the p85 consensus binding
motif, which suggests that additional intermediate proteins are most
likely involved in the
6
4-dependent activation of PI3K. To
identify these intermediates, we analyzed the profile of
phosphoproteins that associate with PI3K after
6
4 ligation. To do
so, cell extracts from mock- (MDA-MB-435/mock) and
4-transfected
(MDA-MB-435/
4) MDA-MB-435 cells that had been clustered with
6-specific antibody 135-13C were immunoprecipitated with a
p85-specific antiserum and the associated proteins were detected by
immunoblotting with phosphotyrosine-specific antibody RC-20. As shown
in Fig. 1A, ligation of both
6
1 and
6
4 resulted in the interaction of PI3K with a 130-kDa
phosphoprotein. However, an additional 180-kDa phosphoprotein
coimmunoprecipitated with PI3K in both of the MDA-MB-435/
4 subclones
after ligation with
6-specific antibodies. To confirm that this
180-kDa protein was specific for
6
4-dependent activation of PI3K,
the MDA-MB-435/
4 transfectants were clustered with
4-specific antibodies, which will not ligate
6
1, and the p85-associated proteins were analyzed. When
6
4 was clustered in the absence of
6
1 ligation, only the 180-kDa protein was observed to
coimmunoprecipitate with PI3K (Fig. 1B). The association of PI3K with
the 180-kDa phosphoprotein only after ligation of the
6
4 integrin
suggests that there is a unique mechanism for PI3K activation by the
6
4 receptor that is not utilized by the
6
1 receptor.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 1.
Analysis of PI3K-associated proteins. Two subclones each
(#1 and #2) of the MDA-MB-435/mock and the MDA-MB-435/ 4
transfectants were maintained in suspension or incubated with either
6- (A) or 4-specific (B) antibodies and allowed to adhere to
either anti-rat IgG- or anti-mouse IgG-coated plates, respectively, for
30 min. Aliquots of cell extracts that contained equivalent amounts of
protein were incubated with a polyclonal antiserum specific for the p85
subunit of PI3K and protein A-Sepharose for 3 h. The immune
complexes were resolved by SDS-8% PAGE and then immunoblotted with
phosphotyrosine-specific antibody RC-20. Mock, MDA-MB-435 cells
transfected with the empty vector; 6 4, MDA-MB-435 cells
transfected with the full-length 4 subunit; S, cells maintained in
suspension; 6, cells clustered with an 6-specific antibody
(135-13C); 4, cells clustered with a 4-specific antibody (UM-A9).
ip, immunoprecipitation.
|
|
To understand further the mechanism of

6

4-dependent PI3K
activation, we sought to identify the 180-kDa protein that was
phosphorylated on tyrosine and associated with PI3K in response
to

6

4 ligation. Given the molecular mass of this phosphoprotein,
we
first investigated if this protein was a growth factor receptor.
This
possibility was supported by the fact that the

6

4 integrin
can
associate with ErbB2 (
21). However, the p85-associated
180-kDa
protein was not expressed on the cell surface, as indicated by
a test for surface biotinylation (data not
shown).
Next, we investigated the IRS adapter proteins. The IRS family members,
which include IRS-1, IRS-2, IRS-3, and IRS-4, are
170- to 180-kDa
proteins (except IRS-3, which is 60 kDa) that
function as intermediate
docking proteins downstream of the insulin
and insulin-like growth
factor 1 (IGF-1) receptors, as well as
a number of cytokine
receptors (
84). In addition, the

5

1 integrin
can
promote IRS-1 phosphorylation in adipocytes (
24).
Importantly,
the IRS proteins contain several PI3K binding sites, and
these
adapters are known to be involved in the activation of PI3K
downstream
of several of the receptors mentioned above (
30,
33,
45,
69,
78,
86). To determine if the 180-kDa protein that
coimmunoprecipitated
with PI3K was an IRS family member, we first
analyzed the expression
of each IRS homolog in MDA-MB-435 cells. As
shown in Fig.
2A,
MDA-MB-435 cells
express very low levels of IRS-1 but express
high levels of IRS-2.
IRS-3 and IRS-4 were not detected in these
cells (data not shown). To
investigate the potential involvement
of IRS-2 in the

6

4-dependent activation of PI3K, cell extracts
from
MDA-MB-435/mock and MDA-MB-435/

4 cells that had been clustered
with

6-specific antibodies were assayed for IRS-2 phosphorylation.
As
shown in Fig.
2B, IRS-2 was phosphorylated on tyrosine in response
to
clustering with

6-specific antibodies in the MDA-MB-435/

4
transfectants but not in the MDA-MB-435/mock transfectants. In
addition, ligation with a

4-specific antibody also increased
the
tyrosine phosphorylation of IRS-2. Most importantly, the p85
subunit of
PI3K associated with IRS-2 after ligation of the

6

4
receptor
(Fig.
2B, bottom). As a positive control for IRS-2 phosphorylation,
the
MDA-MB-435/

4 cells were treated with IGF-1, which increased
the
phosphorylation of IRS-2 and its association with PI3K (Fig.
2B). The
MDA-MB-435/mock and -

4 transfectants express equivalent
levels of
IRS-2, and therefore the lack of IRS-2 phosphorylation
after ligation
of

6

1 in the MDA-MB-435/mock transfectants is
not due to a
relative difference in protein expression levels
(Fig.
2A).

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 2.
Identification of IRS-1 and IRS-2 as 6 4-dependent
PI3K-associated proteins. (A) Aliquots of cell extracts from the
MDA-MB-435 transfectants and T47D breast carcinoma cells containing
equivalent amounts of protein were resolved by SDS-PAGE and
immunoblotted with antibodies specific for IRS-1 and IRS-2. 435, MDA-MB-435 cells; M, MDA-MB-435 cells transfected with the empty
vector; 4, MDA-MB-435 cells transfected with the full-length 4
subunit. (B) MDA-MB-435 transfectants were maintained in suspension or
incubated with either 6- or 4-specific antibodies and allowed to
adhere to either anti-rat IgG- or anti-mouse IgG-coated plates,
respectively, in the absence or presence of IGF-1 (100 ng/ml) for 30 min. Aliquots of cell extracts that contained equivalent amounts of
protein were incubated with an IRS-2-specific polyclonal antibody and
protein A-Sepharose for 3 h. The immune complexes were resolved by
SDS-8% PAGE and then immunoblotted with RC-20 (top). The immunoblot
was subsequently stripped and reprobed with IRS-2- (middle) and
p85-specific (bottom) polyclonal antisera. ip, immunoprecipitation. (C)
MDA-MB-435 transfectants were treated as described above, and aliquots
of cell extracts that contained equivalent amounts of protein were
incubated with an IRS-2-specific antibody and protein A-Sepharose for
3 h. After being washed, the beads were resuspended in kinase
buffer and incubated for 10 min at room temperature. The phosphorylated
lipids were resolved by thin-layer chromatography. Arrows, D3
phosphoinositides. (D) T47D cells were treated as described above, and
aliquots of cell extracts that contained equivalent amounts of protein
were incubated with a p85-specific antibody and protein A-Sepharose for
3 h. The immune complexes were resolved by SDS-8% PAGE and then
immunoblotted with RC-20 (top). The immunoblot was subsequently
stripped and reprobed with an IRS-1-specific polyclonal antibody
(bottom). Mock, MDA-MB-435 cells transfected with the empty vector;
6 4, MDA-MB-435 cells transfected with the full-length 4
subunit; S, cells maintained in suspension; 6, cells clustered with
an 6-specific antibody (135-13C); 4, cells clustered with a
4-specific antibody (UM-A9).
|
|
To confirm that PI3K is activated through IRS-2 in response to

6

4
ligation, in vitro kinase assays were performed on IRS-2
immune
complexes. MDA-MB-435/mock and MDA-MB-435/

4 transfectants
were
clustered with

6- and

4-specific antibodies, and the cell
extracts were immunoprecipitated with IRS-2 antibodies. The IRS-2
immunoprecipitates were assayed for their ability to phosphorylate
crude brain phosphoinositides. As shown in Fig.
2C, ligation of
the

6

4 integrin with both

6- and

4-specific antibodies resulted
in a marked increase in PI3K activity associated with IRS-2, as
demonstrated by the appearance of the
PtdIns-3,4,5-P
3 lipid product.
In
contrast, ligation of

6

1 in the MDA-MB-435/mock transfectants
resulted in minimal IRS-2-associated PI3K
activity.
IRS-1 and IRS-2 have considerable structural homology and both homologs
contain multiple binding sites for PI3K (
84). To
determine
if IRS-1 can also be involved in the activation of PI3K
by the

6

4
integrin, we used T47D breast carcinoma cells, which
express
high levels of IRS-1 and low levels of IRS-2 (Fig.
2A).
As shown in
Fig.
2D (top), ligation of the

6

4 receptor using
either

6- or

4-specific antibodies increased the association
of PI3K with a
170-kDa phosphoprotein. An IRS-1-specific antibody
recognized this
phosphoprotein (bottom). Based on these results
we conclude that both
IRS-1 and IRS-2 can function as intermediate
signaling proteins in the
activation of PI3K by the

6

4 integrin.
The 130-kDa phosphoprotein
that associates with PI3K in response
to

6

1 ligation has not been
conclusively
identified.
Adhesion to laminin-1 promotes
6
4-dependent IRS
phosphorylation.
To confirm that the
6
4-dependent IRS
signaling pathway that we identified by antibody clustering occurs in
response to ligation of
6
4 by a natural extracellular matrix
ligand, we assessed the phosphorylation of IRS-2 after adhesion of the
MDA-MB-435/mock and MDA-MB-435/
4 transfectants to a laminin-1
substratum. As shown in Fig. 3, adhesion
of the MDA-MD-435/mock transfectants to laminin-1 did not result in an
increase in the tyrosine phosphorylation of IRS-2. Given that
6
1
is the major laminin receptor on the surfaces of these cells, these
results confirm the data obtained using antibodies to cluster the
6
1 integrin (Fig. 2B). In contrast, adhesion of the
MDA-MB-435/
4 transfectants to laminin-1 promoted the tyrosine
phosphorylation of IRS-2 and the recruitment of PI3K to this adapter
protein. Therefore, ligation of the
6
4 integrin by either
laminin-1 or receptor-specific antibodies can activate the IRS-PI3K
signaling pathway.

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 3.
6 4-dependent IRS-2 phosphorylation in response to
laminin-1 adhesion. MDA-MB-435 transfectants were maintained in
suspension or allowed to adhere to laminin-1-coated plates for 45 min.
Aliquots of cell extracts that contained equivalent amounts of protein
were incubated with an IRS-2-specific antibody and protein A-Sepharose
for 3 h. The immune complexes were resolved by SDS-8% PAGE and
then immunoblotted with RC-20 (top). The immunoblot was subsequently
stripped and reprobed with IRS-2- (middle) and p85-specific (bottom)
polyclonal antisera. Mock, MDA-MB-435 cells transfected with the empty
vector; 6 4, MDA-MB-435 cells transfected with the full-length
4 subunit; S, cells maintained in suspension; Lam, cells adherent to
a laminin substratum. ip, immunoprecipitation.
|
|
Analysis of tyrosine phosphorylation of the
4 subunit.
Having identified IRS-1 and IRS-2 as signaling intermediates in the
pathway utilized by the
6
4 integrin to activate PI3K, we next
investigated the mechanism by which this integrin receptor activates
this pathway. It had been previously demonstrated that the
4 subunit
is phosphorylated on tyrosine after ligation of the
6
4 receptor
(43). We confirmed this finding in our transfected MDA-MB-435/
4 cells. As shown in Fig.
4A, a
time-dependent increase in the tyrosine phosphorylation of the
4
subunit was observed after ligation of the
6
4 receptor with
6-specific antibodies. Addition of sodium orthovanadate markedly
increased the level of tyrosine phosphorylation, indicating that
tyrosine phosphorylation of the
4 subunit is regulated by tyrosine
phosphatases in these cells (Fig. 4A) (43). To evaluate
the role of
4-tyrosine phosphorylation in the activation of PI3K by
the
6
4 integrin, we analyzed the
4 cytoplasmic domain for
tyrosine residues that were located within known consensus binding or
phosphorylation motifs. We identified two tyrosines that were of
potential interest, Y1257 and Y1494 (Fig. 3B). Both of these tyrosines
are located within immune T-cell inhibitory motifs (ITIM) that have the
consensus sequence of L/VXXpYXL/V and that were initially
identified in immune cell inhibitory coreceptors (79).
ITIM sites are involved in regulating B- and T-cell receptor signaling,
and they have been characterized as binding motifs for the SH2 domains
of the SH2-containing tyrosine phosphatase 1 (SHP-1) and -2 protein
tyrosine phosphatases and also for the SH2-containing inositol
polyphosphate 5-phosphatase 1 (SHIP-1) and -2 lipid phosphatases
(79).

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Characterization of tyrosine mutants of the
4-integrin subunit. (A) MDA-MB-435/ 4 transfectants were
maintained in suspension or incubated with 6-specific antibodies and
allowed to adhere to anti-rat IgG-coated plates in the absence or
presence of 100 µM sodium orthovanadate (van) for 30 min. Aliquots of
cell extracts that contained equivalent amounts of protein were
incubated with a 4-specific antibody (UM-A9) and protein G-Sepharose
for 3 h. The immune complexes were resolved by SDS-8% PAGE and then
immunoblotted with RC-20. (B) Schematic of the 4-integrin subunit
cytoplasmic domain, which indicates the tyrosine residues which were
mutated to phenylalanine. TM, transmembrane domain. (C) Subclones of
transfected MDA-MB-435 cells expressing the 4 subunit on the cell
surface were isolated by FACS using a 4-specific antibody (UM-A9).
MDA-MB-435 cells transfected with the wild-type (WT) and mutant human
4-integrin subunits were analyzed by flow cytometry using
nonspecific mouse IgG (left peak) or UM-A9 (right peak). Shown are two
representative subclones (clones 1 and 2) from each transfectant line.
(D) Aliquots of cell extracts from the MDA-MB-435 transfectants were
immunoprecipitated (ip) with an 6-specific antibody (135-13C). The
immune complexes were resolved by SDS-6% PAGE and immunoblotted with
a polyclonal antiserum that recognizes the C terminus of the 4
subunit.
|
|
To investigate the potential involvement of Y1257 and Y1494 in the

6

4-dependent activation of PI3K, Y1257 and Y1494 in the

4
subunit were individually mutated to phenylalanine residues.
In
addition, we also mutated both Y1257 and Y1494 to generate
a
double-ITIM-mutant

4 subunit (Y1257F/Y1494F). The mutant

4
subunits were stably expressed in the MDA-MB-435 cells, which
lack
endogenous

4 expression, and subclones expressing the

4
mutant
proteins on the cell surface were isolated by FACS. As
shown in the
flow cytometry profiles for two individual subclones
of each
transfectant in Fig.
4C, all of the mutant

4 subunits
were expressed
on the cell surface. To confirm that the mutant

4 subunits
associated with endogenous

6 subunits, cell extracts
of the

4
mutant-expressing subclones were immunoprecipitated
with an

6-specific antibody and then immunoblotted with an antiserum
that
recognizes the C terminus of the

4 subunit. As shown in
Fig.
4D, all
of the mutant

4 subunits formed heterodimers with
the endogenous

6 subunits. Moreover, all of the mutants were
recognized by the
C-terminal antiserum, which indicates that they
are all expressed as
full-length
proteins.
To determine if the

4 cytoplasmic domain is phosphorylated on either
Y1257 or Y1494 in response to

6

4 ligation, we assayed
the
tyrosine phosphorylation of the mutant

4 subunits after clustering
the receptors with

4-specific antibodies. Mutation of either
Y1257
or Y1494 resulted in a significant decrease in the level
of

4-tyrosine phosphorylation (2 to 7% of the wild-type level)
after
clustering with

4-specific antibodies (Fig.
5). Addition
of sodium orthovanadate to
the cells during the clustering markedly
increased the tyrosine
phosphorylation of the mutant

4 subunits.
However, when the results
were normalized for total

4 protein,
a significant decrease
in the tyrosine phosphorylation of the
mutant proteins compared to the
level of phosphorylation of the
wild-type

4 subunit was still
observed.

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis of tyrosine phosphorylation of the 4
subunit. MDA-MB-435/ 4 transfectants were incubated with
4-specific antibodies and allowed to adhere to anti-mouse IgG-coated
plates for 30 min. Aliquots of cell extracts that contained equivalent
amounts of protein were incubated with protein A-Sepharose for 2 h. The immune complexes were resolved by SDS-6% PAGE and then
immunoblotted with RC-20. The immunoblots were subsequently stripped
and reprobed with a 4-specific polyclonal antiserum. Shown are
representative subclones expressing the wild-type (WT) 4 subunit and
each of the 4 mutant subunits. The percentages of phosphorylation of
the mutant 4 subunits compared to that of the wild-type 4 subunit
are indicated below. NaV, sodium orthovanadate.
|
|
Tyrosine 1494 in the
4 subunit is required for
6
4-dependent activation of PI3K.
To evaluate the impact of
mutating Y1257 and Y1494 in the
4-subunit cytoplasmic domain on the
ability of the
6
4 receptor to activate downstream signaling
pathways, we initially examined the ability of these
6
4 mutant
receptors to promote increases in total cellular tyrosine
phosphorylation after clustering with
4-specific antibodies.
MDA-MB-435 cells that expressed the wild-type
4 and each of the
mutant
4 subunits were clustered with
4-specific antibodies, and
the cell extracts were incubated with phosphotyrosine-specific antibody
4G10. As shown in Fig. 6A (top), ligation
of wild-type
6
4 resulted in a marked increase in total cellular
tyrosine phosphorylation levels. A similar increase in tyrosine
phosphorylation was observed in two individual subclones that expressed
the Y1257F
4 subunit, indicating that Y1257 is not essential for
6
4-dependent promotion of tyrosine phosphorylation (Fig. 6A).
Although one of the Y1257F subclones had a lower level of tyrosine
phosphorylation than was observed for the wild-type
4 subclone, this
level of phosphorylation correlated with the levels of surface
expression of the
4 subunit in these cells (Fig. 4C). In contrast,
none of the MDA-MB-435 subclones that expressed the Y1494F or the
double-mutant Y1257F/Y1494F
4 subunits showed increases in
cellular tyrosine phosphorylation levels in response to
6
4
clustering. These results suggest that Y1494 is essential for
6
4-dependent promotion of tyrosine phosphorylation.

View larger version (46K):
[in this window]
[in a new window]
|
FIG. 6.
Analysis of PI3K activity in the MDA-MB-435 mutant 4
transfectants. MDA-MB-435 transfectants were maintained in suspension
or incubated with a 4-specific antibody (UM-A9) and allowed to
adhere to anti-mouse IgG-coated plates for 30 min. Aliquots of cell
extracts that contained equivalent amounts of protein were incubated
with 4G10 and protein A-Sepharose for 3 h. (A) After being washed,
the immune complexes were resolved by SDS-6% PAGE and immunoblotted
with RC-20. Shown are one representative subclone expressing the
wild-type (WT) 4 subunit and two representative subclones of each of
the mutant 4 transfectants. (B) After being washed, the immune
complexes were resuspended in a kinase reaction mixture and incubated
for 10 min at room temperature. The phosphorylated lipids were resolved
by thin-layer chromatography. Arrows, D3-phosphoinositides. S, cells
maintained in suspension; 4, MDA-MB-435 cells clustered with the
4-specific antibody. ip, immunoprecipitation.
|
|
To determine if either Y1257 or Y1494 in the

4 cytoplasmic domain is
required for PI3K activation by the

6

4 receptor, we
assessed the
association of PI3K with the phosphotyrosine immune
complexes after
ligation of

6

4 in the subclones that expressed
these mutant

4
subunits. As shown in Fig.
6A (bottom), p85 association
with the
phosphotyrosine immune complexes increased after the
clustering of the
wild-type

6

4 and the Y1257F mutant

6

4 receptors.
In
contrast, an increase in p85 association with phosphotyrosine
immune
complexes in response to the clustering of the Y1494F and
Y1257F/Y1494F
mutant

6

4 receptors was not observed. The level
of p85 subunit
association with the phosphotyrosine immune complexes
correlated well
with the level of PI3K activity observed in in
vitro kinase assays
(Fig.
6B).
Our data suggest that IRS-2 is an important intermediate in the
activation of PI3K by the

6

4 integrin. Therefore, we examined
the
ability of the mutant

6

4 receptors to promote IRS-2 tyrosine
phosphorylation. As shown in Fig.
7A
(top), mutation of Y1494
inhibited the ability of the

6

4 receptor
to promote IRS-2 phosphorylation.
Tyrosine phosphorylation of IRS-2 was
also inhibited by the double
Y1257F Y1494F

4 mutations.
Moreover, the recruitment of p85 to
IRS-2 in response to

6

4
ligation was prevented in the Y1494F-expressing
and Y1257F
Y1494F-expressing subclones (Fig.
6A, bottom). Although
lower levels of
IRS-2 expression were observed in the Y1494F-expressing
and Y1257F- and
Y1494F-expressing subclones, IRS-2 phosphorylation
in response to

6

4 ligation was not detected even after prolonged
exposure of the
immunoblot. To confirm that the lack of IRS-2
phosphorylation in the
subclones expressing the mutant

4 subunits
was specific to

6

4-dependent signaling, the transfectants were
treated with
IGF-1, which promotes IRS-2 phosphorylation through
IGF-1R. As shown in
Fig.
7B, IRS-2 phosphorylation and PI3K recruitment
in the wild-type
and

4 mutant-expressing subclones after IGF-1
stimulation were
equivalent. Taken together, our results indicate
that Y1494 in the

4
subunit plays a pivotal role in the ability
of the

6

4 integrin to
activate PI3K.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 7.
Analysis of IRS-2 phosphorylation in the MDA-MB-435
mutant 4 transfectants. (A) MDA-MB-435 transfectants were maintained
in suspension or incubated with 4-specific antibodies and allowed to
adhere to anti-mouse IgG-coated plates for 30 min. WT, wild type; ip,
immunoprecipitation. (B) MDA-MB-435 transfectants were incubated in the
presence or absence of IGF-1 (100 ng/ml) for 5 min. Aliquots of cell
extracts from equivalent numbers of cells were incubated with an
IRS-2-specific antibody and protein A-Sepharose for 3 h. The
immune complexes were resolved by SDS-6% PAGE and then immunoblotted
with RC-20 (top). The immunoblots were subsequently stripped and
reprobed with IRS-2-specified (middle) and p85-specific (bottom)
polyclonal antisera.
|
|
Tyrosine 1494 in the
4 subunit is required for
6
4-dependent invasion.
Expression of the
4 subunit
increases the invasive potential of MDA-MB-435 cells, and we have
hypothesized that this ability to promote invasion involves activation
of PI3K by the
6
4 receptor (64). If this prediction
is correct, expression of the Y1494F and Y1257F/Y1494F
4 mutant
subunits in MDA-MB-435 cells should not increase their invasive
potential. To address this question, subclones expressing the wild-type
and mutant
4 subunits were assayed for their ability to invade
Matrigel using a modified Boyden chamber assay. The MDA-MB-435
subclones expressing the Y1257F mutant subunit invaded to the same
extent as the MDA-MB-435 subclone that expressed the wild-type
4
subunit (Fig. 8A). In contrast, the
MDA-MB-435 subclones that expressed the Y1494F and Y1257F/Y1494F mutant
4 subunits did not invade. In fact, invasion was reduced below the
level observed for the MDA-MB-435/mock transfectants, which suggests
that the Y1494F and Y1257F/Y1494F mutant
4 subunits act in a
dominant-negative manner for invasion.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 8.
Analysis of invasion and adhesion by the MDA-MB-435
mutant 4 transfectants. (A) MDA-MB-435 transfectants were assayed
for their ability to invade Matrigel. Matrigel was diluted in cold
distilled water, added to the upper well of Transwell chambers, and
dried in a sterile hood. The Matrigel was reconstituted with medium,
and the transfectants (5 × 104) were added to each
well. Conditioned NIH 3T3 medium was added to the bottom wells of the
chambers. After 4 h at 37°C, the cells that had not invaded were
removed and the cells that had invaded to the lower surface of the
filters were fixed, stained, and quantitated as described in Materials
and Methods. The data shown are from one (mock and wild-type [WT]
4) or two ( 4 mutants) individual subclones of each transfectant
and are the mean values (± standard deviations [SD]) of a
representative experiment done in triplicate. M, MDA-MB-435 cells
transfected with vector alone; WT 4, MDA-MB-435 cells transfected
with the wild-type 4 subunit. (B) MDA-MB-435 transfectants were
assayed for their ability to adhere to laminin-1 and collagen I
substrata. Forty-eight-well plates were coated overnight with 20 µg
of laminin-1 or collagen I/ml (200 µl/well). The transfectants
(105) were added to each well, and the plates were
incubated for 1 h at 37°C. After being washed, the cells were
fixed, stained, and quantitated as described in Materials and Methods.
The data shown are the mean values (± SD) from a representative
experiment done in triplicate.
|
|
The lack of invasion in the mutant

4 transfectants could result from
a deficiency in adhesion. To examine if the observed
decrease in
invasion of the Y1494F and Y1257F/Y1494F transfectants
was related to a
decrease in cell adhesion, the ability of these
cells to adhere to a
laminin-1 or collagen I substrate was assessed.
As shown in Fig.
8B,
the Y1494F and Y1257F/Y1494F transfectants
demonstrated a 1.5- to
2-fold higher level of adhesion to both
substrates than the mock,
wild-type

4, and Y1257 transfectants.
The increased adhesion was not
due to higher levels of receptor
expression in the Y1494F and
Y1257F/Y1494F transfectants (data
not shown). Interestingly, the
haptotactic migration of the Y1494F
and Y1257F/Y1494F transfectants was
significantly diminished on
both laminin-1 and collagen I substrata
(data not shown). The
increased adhesive strength of the mutant

4
transfectants may
inhibit their motility, which would impede the
ability of these
cells to invade (
37). These results
suggest that the Y1494 of
the

4 subunit is important for regulating
dynamic adhesion and
that, in the absence of the IRS-2-PI3K signaling
pathway activated
through this tyrosine residue, other signals from the

6

4 receptor
may promote stable
adhesion.
 |
DISCUSSION |
Our results establish that the
6
4 integrin activates PI3K
through the signaling adapters IRS-1 and IRS-2. This is a unique mechanism for
6
4 because the IRS proteins are not involved in PI3K activation downstream of the
6
1 receptor. We have also identified a specific tyrosine residue in the
4 cytoplasmic domain, Y1494, which is essential for the activation of PI3K and for the ability of the
6
4 integrin to promote carcinoma invasion. Taken together, our findings highlight a novel mechanism for
6
4-dependent signaling and for the ability of this integrin to
promote carcinoma invasion.
Invasion is thought to be the essential first step for tumor cells in
the metastatic cascade (14). The correlation between metastasis and patient mortality provides a strong impetus to elucidate
the mechanisms involved in this transition. One approach to
understanding how carcinoma cells acquire a motile, invasive phenotype
is to dissect the cellular alterations that occur to drive this complex
process. In this regard, previous work, including our own, has
established that the
6
4 integrin can promote carcinoma invasion
(12, 21, 64, 67). We determined that activation of PI3K
was not only essential but also sufficient to increase the invasive
potential of carcinoma cells, which emphasized the importance of
investigating further the mechanism of
6
4 activation of this
signaling pathway (64). We have now added to our
understanding of this "invasion pathway" by establishing that IRS
proteins IRS-1 and IRS-2 are upstream mediators in the activation of
PI3K by the
6
4 integrin. This is the first report of an
involvement of the IRS family in tumor invasion, and it establishes a
new area of research for these proteins, which have been studied
primarily for their role in metabolic regulation (84).
The role of the IRS proteins in
6
4-dependent promotion of tumor
progression adds to other studies that have demonstrated an involvement
of the IRS family in cancer. IRS-1 and IRS-2 are essential downstream
effectors of IGF-1R, which is frequently overexpressed in tumors and
which is a prognostic indicator of tumor recurrence and reduced patient
survival (39, 77). Although only a limited number of
studies have been performed to address directly the contribution of IRS
function to cancer, the data to date support an important role for
these proteins in tumor biology. For example, in breast cancer, an
essential role for IRS-1 in IGF-1-dependent breast carcinoma cell
survival and an involvement in IGF-1-dependent breast carcinoma cell
growth have been observed (50). IRS-1 expression is
regulated by estrogen, and the levels of IRS-1 are decreased in
response to antiestrogens such as tamoxifen and ICI 182,780 (25, 60). This regulation of IRS-1 expression has been
hypothesized to be a mechanism by which these antiestrogens inhibit
breast carcinoma growth. Finally, high levels of IRS-1 expression in
primary human breast cancers predict a greater incidence of recurrence
and a decreased patient survival rate (58). Increased
IRS-1 expression levels have also been observed in early stages of
hepatocellular carcinoma, and a dominant-negative IRS-1 protein can
reverse the malignant phenotype of transformed hepatocellular carcinoma
cell lines (49, 73). Finally, IRS-1 and IRS-2 are both
overexpressed in pancreatic cancer (36). It is intriguing
to speculate that the correlations of IRS expression with tumor
progression are related at least in part to the functions of the IRS
proteins downstream of the
6
4 integrin.
The identification of IRS-1 and IRS-2 as signaling intermediates for
the
6
4 integrin is significant because these proteins have the
potential to regulate multiple signaling pathways downstream of this
integrin receptor. IRS-1 and IRS-2 are cytoplasmic adapter proteins
that do not contain intrinsic kinase activity but rather function by
recruiting proteins to surface receptors, where they organize signaling
complexes (84). These proteins belong to the IRS family,
which includes IRS-1, IRS-2, IRS-3, and IRS-4. IRS-1 and IRS-2 are
expressed ubiquitously, whereas the IRS-3 and IRS-4 homologs are more
restricted in their localization (84). All of the IRS
family members have homology and contain multiple binding motifs that
are essential for their interaction with downstream effectors, which
can include PI3K, Grb-2, SHP-2, Nck, Fyn, phospholipase C-
, and Crk
(4, 40, 46, 47, 66, 68, 69). With their ability to recruit
such a variety of signaling molecules, the IRS proteins, not
surprisingly, have been implicated in numerous cellular functions
including mitogenesis, cell survival, gene transcription, and glucose
transport (84). With regard to the involvement of the IRS
proteins in
6
4-dependent signaling, we have identified PI3K as
one downstream effector that is recruited to these adapter proteins in
response to receptor ligation. The IRS-dependent activation of PI3K is
important for the ability of
6
4 to promote invasion, an essential
function of metastatic cells. Moreover, given the potential of the IRS
proteins to interact with many other signaling effectors, other
6
4-dependent signals may also be regulated through these adapter
proteins. For example, although we have observed MAPK activation in
response to
6
4 ligation in the MDA-MB-435/
4 transfectants, we
have not observed Shc phosphorylation, a proposed mechanism for MAPK
activation (16, 43). An alternative mechanism for MAPK
activation downstream of the
6
4 integrin could be IRS recruitment
of Grb2. In support of this, we have not observed MAPK
activation in the Y1494 mutant transfectants (data not shown).
Our demonstration that the
6
4 integrin is capable of stimulating
the phosphorylation of both IRS-1 and IRS-2 raises the question of
whether these homologs serve identical or distinct functions downstream
of this integrin receptor. Although IRS-1 and IRS-2 share overall
structural features and have some common effector binding sites, they
also have unique phosphorylation sites (84). Furthermore,
there are a number of reports that suggest that these homologs have
different functions. For example, overexpression of IRS-1, but not
IRS-2, in IRS-1 null fibroblasts restores IGF-1 stimulated cell cycle
progression to the level observed in normal fibroblasts
(8). In addition, IGF-1 stimulation of fetal brown
adipocytes results in the association of Grb-2 with IRS-1 but not with
IRS-2 (80). Differences in intracellular localization have
also been demonstrated for IRS-1 and IRS-2, and this may explain some
of the functional distinctions between these two homologs
(28). The most striking evidence for functional differences in IRS-1 and IRS-2 comes from the phenotype of the IRS-1
and IRS-2 knockout mice. IRS-1 null mice are stunted in their growth,
but they do not develop diabetes (1). In contrast, IRS-2
null mice develop insulin resistance in the liver and skeletal muscle
and progressively lose their ability to regulate glucose homeostasis
(85). The question of distinct IRS homolog function in
carcinoma cells is relevant because differences in the expression and
activity of IRS-1 and IRS-2 in tumor cells have been reported. For
example, IRS-1 and IRS-2 are predominantly expressed in estrogen receptor positive (ER+) and
ER
breast carcinoma cells, respectively
(29). If IRS-1 and IRS-2 activate distinct downstream
pathways, the function of the
6
4 receptor would depend on which
IRS homolog was activated in response to receptor ligation. Therefore,
although the
6
4 integrin can promote the phosphorylation of both
IRS-1 and IRS-2, it is intriguing to speculate that
6
4-dependent
signaling in carcinoma cells could be influenced by factors that
differentially regulate the expression of the IRS proteins.
One issue that arises from our identification of IRS-1 and IRS-2 as
downstream effectors of the
6
4 receptor is how the
phosphorylation of these adapters is regulated by this integrin
receptor. The IRS proteins were first discovered as signaling
intermediates of the insulin receptor (IR), and they bind to a
consensus sequence in the IR, where they are phosphorylated directly by
the intrinsic receptor kinase domain (84). Although the
IRS consensus binding site is also present in the IGF-1R and
interleukin-4 (IL-4) receptor, not all receptors that promote IRS
phosphorylation contain this binding motif, including the
6
4
integrin (15, 26, 32). In addition, none of these
receptors possess intrinsic kinase domains. Therefore, alternative
mechanisms for the recruitment and phosphorylation of the IRS proteins
are necessary. Several models for
6
4-dependent activation of the
IRS proteins could be proposed based on the mechanisms utilized by
other members of this group of receptors that lack the IRS binding
motif. One potential model involves the JAK family of tyrosine kinases,
which includes JAK1, JAK2, JAK3, and Tyk2 (42). Several
receptors, including those for alpha interferon, prolactin, growth
hormone, and cytokines IL-2, -4, -7, and -15, associate with members of the JAK family, and these kinases recruit and phosphorylate the IRS
proteins upon receptor stimulation (30, 53, 86). A second model involves the phosphorylation of the IRS proteins by members of
the src-kinase family (17). However, it is not clear how the IRS proteins are recruited to receptor complexes for this src-dependent phosphorylation to occur. Focal adhesion kinase (FAK) has
also been shown to associate with and promote phosphorylation of IRS-1
(38). However, the FAK-dependent phosphorylation may be
indirect due to recruitment of src to the protein complexes. Finally,
the possibility that the
6
4 receptor interacts with the IRS
proteins through an association with other surface receptors is also
valid. For example, the
v
3 integrin can recruit IRS-1 indirectly to receptor complexes through an interaction with the insulin receptor (61, 83). The elucidation of the
mechanism involved in the
6
4-dependent phosphorylation of the IRS
proteins will provide additional targets for the disruption of tumor invasion.
We have identified a single amino acid in the
4 cytoplasmic domain,
Y1494, which is involved in promoting the
6
4-IRS-PI3K invasion
pathway. Mutation of this tyrosine residue inhibited not only
6
4-dependent activation of PI3K but also the ability of this
receptor to promote carcinoma invasion. The fact that mutation of Y1494
had such a dramatic impact on
6
4-dependent signaling emphasizes
the likelihood that this residue is an essential binding site for
downstream effectors of the
6
4 receptor. We specifically selected
Y1257 and Y1494 for mutation based on the location of these tyrosines
within ITIM consensus binding motifs (79). The presence of
both of these tyrosines within ITIM motifs might suggest that these
residues have similar functions. However, it is clear that mutation of
Y1257 in the
4 subunit does not disrupt the signaling functions of
the
6
4 integrin, as was observed when Y1494 was mutated, even
though both of these tyrosines appear to be phosphorylated in response
to
6
4 ligation. These findings indicate that the two ITIM motifs
in the
4 subunit do not function equally and that the specific
sequences surrounding Y1257 and Y1494 must be important for regulating
6
4-dependent signals. ITIM motifs are known to be potential
binding sites for the SH2 domains of tyrosine phosphatases SHP-1 and
SHP-2 and lipid phosphatases SHIP-1 and SHIP-2 (79). SHP-1
and -2 phosphatases regulate tyrosine kinase signaling pathways,
whereas the SHIP-1 and -2 phosphatases regulate the PI3K signaling
pathway (reviewed in references 59 and 65). Disruption of
either pathway could produce the phenotype we observed with the mutant
receptors. For example, the phosphorylation of the
4 subunit is
tightly regulated by tyrosine phosphatases, and this supports the
potential involvement of SHP-2 (Fig. 5). The fact that IRS-2 is not
phosphorylated in response to ligation of the Y1494 mutant receptor
indicates that this tyrosine could be involved in the recruitment of
IRS-2 to the receptor. However, it is also possible that Y1494 is
essential for recruiting the kinase that regulates the phosphorylation
of IRS-2 or other essential binding sites in the
4 subunit.
In summary, we have identified a novel mechanism for the activation of
PI3K by the
6
4 integrin that involves IRS-1 and IRS-2 and
requires Y1494 in the
4 cytoplasmic domain. Activation of this
6
4-IRS-PI3K signaling pathway promotes carcinoma invasion.
 |
ACKNOWLEDGMENTS |
I thank Yumiko Honzako for excellent technical assistance.
This work was supported by NIH grant CA81325 and U.S. Army grant
DAMD17-97-1-7313.
 |
FOOTNOTES |
*
Mailing address: Department of Pathology, Beth Israel
Deaconess Medical Center-RN227, 330 Brookline Ave., Boston, MA 02215. Phone: (617) 667-1430. Fax: (617) 667-3616. E-mail:
lshaw{at}caregroup.harvard.edu.
 |
REFERENCES |
| 1.
|
Araki, E.,
M. A. Lipes,
M. E. Patti,
J. C. Bruning,
B. Haag III,
R. S. Johnson, and C. R. Kahn.
1994.
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene.
Nature
372:186-190[CrossRef][Medline].
|
| 2.
|
Bachelder, R. E.,
A. Marchetti,
R. Falcioni,
S. Soddu, and A. M. Mercurio.
1999.
Activation of p53 function in carcinoma cells by the alpha6beta4 integrin.
J. Biol. Chem.
274:20733-20737[Abstract/Free Full Text].
|
| 3.
|
Bachelder, R. E.,
M. J. Ribick,
A. Marchetti,
R. Falcioni,
S. Soddu,
K. R. Davis, and A. M. Mercurio.
1999.
p53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB.
J. Cell Biol.
147:1063-1072[Abstract/Free Full Text].
|
| 4.
|
Beitner-Johnson, D.,
V. A. Blakesley,
Z. Shen-Orr,
M. Jimenez,
B. Stannard,
L. M. Wang,
J. Pierce, and D. LeRoith.
1996.
The proto-oncogene product c-Crk associates with insulin receptor substrate-1 and 4PS. Modulation by insulin growth factor-I (IGF) and enhanced IGF-I signaling.
J. Biol. Chem.
271:9287-9290[Abstract/Free Full Text].
|
| 5.
|
Birchmeier, W.
1995.
E-cadherin as a tumor (invasion) suppressor gene.
Bioessays
17:97-99[CrossRef][Medline].
|
| 6.
|
Bonaccorsi, L.,
V. Carloni,
M. Muratori,
A. Salvadori,
A. Giannini,
M. Carini,
M. Serio,
G. Forti, and E. Baldi.
2000.
Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype.
Endocrinology
141:3172-3182[Abstract/Free Full Text].
|
| 7.
|
Borradori, L., and A. Sonnenberg.
1999.
Structure and function of hemidesmosomes: more than simple adhesion complexes.
J. Investig. Dermatol.
112:411-418[CrossRef][Medline].
|
| 8.
|
Bruning, J. C.,
J. Winnay,
B. Cheatham, and C. R. Kahn.
1997.
Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells.
Mol. Cell. Biol.
17:1513-1521[Abstract].
|
| 9.
|
Cantley, L. C., and B. G. Neel.
1999.
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway.
Proc. Natl. Acad. Sci. USA
96:4240-4245[Abstract/Free Full Text].
|
| 10.
|
Cantley, L. C., and Z. Songyang.
1994.
Specificity in recognition of phosphopeptides by src-homology 2 domains.
J. Cell Sci. Supplement
18:121-126[Medline].
|
| 11.
|
Chang, H. W.,
M. Aoki,
D. Fruman,
K. R. Auger,
A. Bellacosa,
P. N. Tsichlis,
L. C. Cantley,
T. M. Roberts, and P. K. Vogt.
1997.
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
Science
276:1848-1850[Abstract/Free Full Text].
|
| 12.
|
Chao, C.,
M. M. Lotz,
A. C. Clarke, and A. M. Mercurio.
1996.
A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells.
Cancer Res.
56:4811-4819[Abstract/Free Full Text].
|
| 13.
|
Clarke, A. S.,
M. M. Lotz, and A. M. Mercurio.
1994.
A novel structural variant of the human beta 4 integrin cDNA.
Cell Adhesion Commun.
2:1-6[Medline].
|
| 14.
|
Cotran, R. S.,
V. Kumar, and T. Collins.
1998.
Robbins pathologic basis of disease, 6th ed.
The W. B. Saunders Co., Philadelphia, Pa.
|
| 15.
|
Craparo, A.,
T. J. O'Neill, and T. A. Gustafson.
1995.
Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.
J. Biol. Chem.
270:15639-15643[Abstract/Free Full Text].
|
| 16.
|
Dans, M.,
L. Gagnoux-Palacios,
P. Blaikie,
S. Klein,
A. Mariotti, and F. G. Giancotti.
2001.
Tyrosine phosphorylation of the beta 4 integrin cytoplasmic domain mediates Shc signaling to extracellular signal-regulated kinase and antagonizes formation of hemidesmosomes.
J. Biol. Chem.
276:1494-1502[Abstract/Free Full Text].
|
| 17.
|
Daulhac, L.,
A. Kowalski-Chauvel,
L. Pradayrol,
N. Vaysse, and C. Seva.
1999.
Src-family tyrosine kinases in activation of ERK-1 and p85/p110-phosphatidylinositol 3-kinase by G/CCKB receptors.
J. Biol. Chem.
274:20657-20663[Abstract/Free Full Text].
|
| 18.
|
Di Cristofano, A., and P. P. Pandolfi.
2000.
The multiple roles of PTEN in tumor suppression.
Cell
100:387-390[CrossRef][Medline].
|
| 19.
|
Dowling, J.,
Q. C. Yu, and E. Fuchs.
1996.
Beta-4 integrin is required for hemidesmosome formation, cell adhesion and cell survival.
J. Cell Biol.
134:559-572[Abstract/Free Full Text].
|
| 20.
|
Dudek, H.,
S. R. Datta,
T. F. Franke,
M. J. Birnbaum,
R. Yao,
G. M. Cooper,
R. A. Segal,
D. R. Kaplan, and M. E. Greenberg.
1997.
Regulation of neuronal survival by the serine-threonine protein kinase Akt.
Science
275:661-665[Abstract/Free Full Text].
|
| 21.
|
Falcioni, R.,
A. Antonini,
P. Nistico,
S. Di Stefano,
M. Crescenzi,
P. G. Natali, and A. Sacchi.
1997.
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines.
Exp. Cell Res.
236:76-85[CrossRef][Medline].
|
| 22.
|
Falcioni, R.,
A. Sacchi,
J. Resau, and S. J. Kennel.
1988.
Monoclonal antibody to human carcinoma-associated protein complex: quantitation in normal and tumor tissue.
Cancer Res.
48:816-821[Abstract/Free Full Text].
|
| 23.
|
Falcioni, R.,
V. Turchi,
P. Vittulo,
G. Navarra,
F. Ficari,
F. Cavaliere,
A. Sacchi, and R. Mariani-Costantini.
1994.
Integrin beta 4 expression in colorectal cancer.
Int. J. Oncol.
5:573-578.
|
| 24.
|
Guilherme, A., and M. P. Czech.
1998.
Stimulation of IRS-1-associated phosphatidylinositol 3-kinase and Akt/protein kinase B but not glucose transport by beta1-integrin signaling in rat adipocytes.
J. Biol. Chem.
273:33119-33122[Abstract/Free Full Text].
|
| 25.
|
Guvakova, M. A., and E. Surmacz.
1997.
Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
Cancer Res.
57:2606-2610[Abstract/Free Full Text].
|
| 26.
|
He, W.,
A. Craparo,
Y. Zhu,
T. J. O'Neill,
L. M. Wang,
J. H. Pierce, and T. A. Gustafson.
1996.
Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2.
J. Biol. Chem.
271:11641-11645[Abstract/Free Full Text].
|
| 27.
|
Hogervorst, F.,
I. Kuikman,
A. E. von dem Borne, and A. Sonnenberg.
1990.
Cloning and sequence analysis of beta-4 cDNA: an integrin subunit that contains a unique 118 kd cytoplasmic domain.
EMBO J.
9:765-770[Medline].
|
| 28.
|
Inoue, G.,
B. Cheatham,
R. Emkey, and C. R. Kahn.
1998.
Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2.
J. Biol. Chem.
273:11548-11555[Abstract/Free Full Text].
|
| 29.
|
Jackson, J. G.,
M. F. White, and D. Yee.
1998.
Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.
J. Biol. Chem.
273:9994-10003[Abstract/Free Full Text].
|
| 30.
|
Johnston, J. A.,
L. M. Wang,
E. P. Hanson,
X. J. Sun,
M. F. White,
S. A. Oakes,
J. H. Pierce, and J. J. O'Shea.
1995.
Interleukins 2, 4, 7, and 15 stimulate tyrosine phosphorylation of insulin receptor substrates 1 and 2 in T cells. Potential role of JAK kinases.
J. Biol. Chem.
270:28527-28530[Abstract/Free Full Text].
|
| 31.
|
Juliano, R. L., and J. A. Varner.
1993.
Adhesion molecules in cancer: the role of integrins.
Curr. Opin. Cell Biol.
5:812-818[CrossRef][Medline].
|
| 32.
|
Keegan, A. D.,
K. Nelms,
M. White,
L. M. Wang,
J. H. Pierce, and W. E. Paul.
1994.
An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth.
Cell
76:811-820[CrossRef][Medline].
|
| 33.
|
Kellerer, M.,
M. Koch,
E. Metzinger,
J. Mushack,
E. Capp, and H. U. Haring.
1997.
Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways.
Diabetologia
40:1358-1362[CrossRef][Medline].
|
| 34.
|
Kennedy, S. G.,
A. J. Wagner,
S. D. Conzen,
J. Jordan,
A. Bellacosa,
P. N. Tsichlis, and N. Hay.
1997.
The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal.
Genes Dev.
11:701-713[Abstract/Free Full Text].
|
| 35.
|
Khwaja, A.,
P. Rodriguez-Viciana,
S. Wennstrom,
P. H. Warne, and J. Downward.
1997.
Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway.
EMBO J.
16:2783-2793[CrossRef][Medline].
|
| 36.
|
Kornmann, M.,
H. Maruyama,
U. Bergmann,
P. Tangvoranuntakul,
H. G. Beger,
M. F. White, and M. Korc.
1998.
Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer.
Cancer Res.
58:4250-4254[Abstract/Free Full Text].
|
| 37.
|
Lauffenburger, D. A., and A. F. Horwitz.
1996.
Cell migration: a physically integrated molecular process.
Cell
84:359-369[CrossRef][Medline].
|
| 38.
|
Lebrun, P.,
I. Mothe-Satney,
L. Delahaye,
E. van Obberghen, and V. Baron.
1998.
Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125(FAK) and pp60(src).
J. Biol. Chem.
273:32244-32253[Abstract/Free Full Text].
|
| 39.
|
Lee, A. V.,
J. G. Jackson,
J. L. Gooch,
S. G. Hilsenbeck,
E. Coronado-Heinsohn,
C. K. Osborne, and D. Yee.
1999.
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.
Mol. Endocrinol.
13:787-796[Abstract/Free Full Text].
|
| 40.
|
Lee, C. H.,
W. Li,
R. Nishimura,
M. Zhou,
A. G. Batzer,
M. G. Myers, Jr.,
M. F. White,
J. Schlessinger, and E. Y. Skolnik.
1993.
Nck associates with the SH2 domain-docking protein IRS-1 in insulin-stimulated cells.
Proc. Natl. Acad. Sci. USA
90:11713-11717[Abstract/Free Full Text].
|
| 41.
|
Lee, E. C.,
M. M. Lotz,
G. D. Steele, Jr., and A. M. Mercurio.
1992.
The integrin alpha 6 beta 4 is a laminin receptor.
J. Cell Biol.
117:671-678[Abstract/Free Full Text].
|
| 42.
|
Liu, K. D.,
S. L. Gaffen, and M. A. Goldsmith.
1998.
JAK/STAT signaling by cytokine receptors.
Curr. Opin. Immunol.
10:271-278[CrossRef][Medline].
|
| 43.
|
Mainiero, F.,
A. Pepe,
K. K. Wary,
L. Spinardi,
M. Mohammadi,
J. Schlessinger, and F. G. Giancotti.
1995.
Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes.
EMBO J.
14:4470-4481[Medline].
|
| 44.
|
Murgia, C.,
P. Blaikie,
N. Kim,
M. Dans,
H. T. Petrie, and F. G. Giancotti.
1998.
Cell cycle and adhesion defects in mice carrying a targeted deletion of the integrin beta4 cytoplasmic domain.
EMBO J.
17:3940-3951[CrossRef][Medline].
|
| 45.
|
Myers, M. G., Jr.,
J. M. Backer,
X. J. Sun,
S. Shoelson,
P. Hu,
J. Schlessinger,
M. Yoakim,
B. Schaffhausen, and M. F. White.
1992.
IRS-1 activates phosphatidylinositol 3'-kinase by associating with src homology 2 domains of p85.
Proc. Natl. Acad. Sci. USA
89:10350-10354[Abstract/Free Full Text].
|
| 46.
|
Myers, M. G., Jr.,
R. Mendez,
P. Shi,
J. H. Pierce,
R. Rhoads, and M. F. White.
1998.
The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling.
J. Biol. Chem.
273:26908-26914[Abstract/Free Full Text].
|
| 47.
|
Myers, M. G., Jr.,
L. M. Wang,
X. J. Sun,
Y. Zhang,
L. Yenush,
J. Schlessinger,
J. H. Pierce, and M. F. White.
1994.
Role of IRS-1-GRB-2 complexes in insulin signaling.
Mol. Cell. Biol.
14:3577-3587[Abstract/Free Full Text].
|
| 48.
|
Niessen, C. M.,
E. H. Hulsman,
E. S. Rots,
P. Sanchez-Aparicio, and A. Sonnenberg.
1997.
Integrin alpha 6 beta 4 forms a complex with the cytoskeletal protein HD1 and induces its redistribution in transfected COS-7 cells.
Mol. Biol. Cell
8:555-566[Abstract].
|
| 49.
|
Nishiyama, M., and J. R. Wands.
1992.
Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma.
Biochem. Biophys. Res. Commun.
183:280-285[CrossRef][Medline].
|
| 50.
|
Nolan, M. K.,
L. Jankowska,
M. Prisco,
S. Xu,
M. A. Guvakova, and E. Surmacz.
1997.
Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells.
Int. J. Cancer
72:828-834[CrossRef][Medline].
|
| 51.
|
O'Connor, K. L.,
B. K. Nguyen, and A. M. Mercurio.
2000.
RhoA function in lamellae formation and migration is regulated by the alpha6beta4 integrin and cAMP metabolism.
J. Cell Biol.
148:253-258[Abstract/Free Full Text].
|
| 52.
|
O'Connor, K. L.,
L. M. Shaw, and A. M. Mercurio.
1998.
Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells.
J. Cell Biol.
143:1749-1760[Abstract/Free Full Text].
|
| 53.
|
Platanias, L. C.,
S. Uddin,
A. Yetter,
X. J. Sun, and M. F. White.
1996.
The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2.
J. Biol. Chem.
271:278-282[Abstract/Free Full Text].
|
| 54.
|
Rabinovitz, I., and A. M. Mercurio.
1997.
The integrin alpha6beta4 functions in carcinoma cell migration on laminin-1 by mediating the formation and stabilization of actin-containing motility structures.
J. Cell Biol.
139:1873-1884[Abstract/Free Full Text].
|
| 55.
|
Rabinovitz, I., and A. M. Mercurio.
1996.
The integrin alpha 6 beta 4 and the biology of carcinoma.
Biochem. Cell Biol.
74:811-821[Medline].
|
| 56.
|
Rabinovitz, I.,
A. Toker, and A. M. Mercurio.
1999.
Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells.
J. Cell Biol.
146:1147-1160[Abstract/Free Full Text].
|
| 57.
|
Rezniczek, G. A.,
J. M. de Pereda,
S. Reipert, and G. Wiche.
1998.
Linking integrin alpha6beta4-based cell adhesion to the intermediate filament cytoskeleton: direct interaction between the beta4 subunit and plectin at multiple molecular sites.
J. Cell Biol.
141:209-225[Abstract/Free Full Text].
|
| 58.
|
Rocha, R. L.,
S. G. Hilsenbeck,
J. G. Jackson,
C. L. VanDenBerg,
C. Weng,
A. V. Lee, and D. Yee.
1997.
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.
Clin. Cancer Res.
3:103-109[Abstract].
|
| 59.
|
Rohrschneider, L. R.,
J. F. Fuller,
I. Wolf,
Y. Liu, and D. M. Lucas.
2000.
Structure, function, and biology of SHIP proteins.
Genes Dev.
14:505-520[Free Full Text].
|
| 60.
|
Salerno, M.,
D. Sisci,
L. Mauro,
M. A. Guvakova,
S. Ando, and E. Surmacz.
1999.
Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells.
Int. J. Cancer
81:299-304[CrossRef][Medline].
|
| 61.
|
Schneller, M.,
K. Vuori, and E. Ruoslahti.
1997.
Alphabeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF.
EMBO J.
16:5600-5607[CrossRef][Medline].
|
| 62.
|
Serini, G.,
L. Trusolino,
E. Saggiorato,
O. Cremona,
M. De Rossi,
A. Angeli,
F. Orlandi, and P. C. Marchisio.
1996.
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue.
J. Natl. Cancer Inst.
88:442-449[Abstract/Free Full Text].
|
| 63.
|
Shaw, L. M.,
C. Chao,
U. M. Wewer, and A. M. Mercurio.
1996.
Function of the integrin alpha 6 beta 1 in metastatic breast carcinoma cells assessed by expression of a dominant-negative receptor.
Cancer Res.
56:959-963[Abstract/Free Full Text].
|
| 64.
|
Shaw, L. M.,
I. Rabinovitz,
H. H. F. Wang,
A. Toker, and A. M. Mercurio.
1997.
Activation of phosphoinositide 3-OH kinase by the alpha-6-beta-4 integrin promotes carcinoma invasion.
Cell
91:949-960[CrossRef][Medline].
|
| 65.
|
Siminovitch, K. A., and B. G. Neel.
1998.
Regulation of B cell signal transduction by SH2-containing protein-tyrosine phosphatases.
Semin. Immunol.
10:329-347[CrossRef][Medline].
|
| 66.
|
Sozzani, P.,
L. Hasan,
M. H. Seguelas,
D. Caput,
P. Ferrara,
B. Pipy, and C. Cambon.
1998.
IL-13 induces tyrosine phosphorylation of phospholipase C gamma-1 following IRS-2 association in human monocytes: relationship with the inhibitory effect of IL-13 on ROI production.
Biochem. Biophys. Res. Commun.
244:665-670[CrossRef][Medline].
|
| 67.
|
Sun, H.,
S. A. Santoro, and M. M. Zutter.
1998.
Downstream events in mammary gland morphogenesis mediated by reexpression of the alpha2beta1 integrin: the role of the alpha6 and beta4 integrin subunits.
Cancer Res.
58:2224-2233[Abstract/Free Full Text].
|
| 68.
|
Sun, X. J.,
S. Pons,
T. Asano,
M. G. Myers, Jr.,
E. Glasheen, and M. F. White.
1996.
The Fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation.
J. Biol. Chem.
271:10583-10587[Abstract/Free Full Text].
|
| 69.
|
Sun, X. J.,
P. Rothenberg,
C. R. Kahn,
J. M. Backer,
E. Araki,
P. A. Wilden,
D. A. Cahill,
B. J. Goldstein, and M. F. White.
1991.
Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein.
Nature
352:73-77[CrossRef][Medline].
|
| 70.
|
Suzuki, S., and Y. Naitoh.
1990.
Amino acid sequence of a novel integrin beta 4 subunit and primary expression of the mRNA in epithelial cells.
EMBO J.
9:757-763[Medline].
|
| 71.
|
Tagliabue, E.,
C. Ghirelli,
P. Squicciarini,
P. Aiello,
M. I. Colnaghi, and S. Menard.
1998.
Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells.
Clin. Cancer Res.
4:407-410[Abstract/Free Full Text].
|
| 72.
|
Tamura, R. N.,
C. Rozzo,
L. Starr,
J. Chambers,
L. F. Reichardt,
H. M. Cooper, and V. Quaranta.
1990.
Epithelial integrin alpha 6 beta 4: complete primary structure of alpha 6 and variant forms of beta 4.
J. Cell Biol.
111:1593-1604[Abstract/Free Full Text].
|
| 73.
|
Tanaka, S., and J. R. Wands.
1996.
A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype.
J. Clin. Investig.
98:2100-2108[Medline].
|
| 74.
|
Tang, K.,
D. Nie,
Y. Cai, and K. V. Honn.
1999.
The beta4 integrin subunit rescues A431 cells from apoptosis through a PI3K/Akt kinase signaling pathway.
Biochem. Biophys. Res. Commun.
264:127-132[CrossRef][Medline].
|
| 75.
|
Tani, T.,
T. Karttunen,
T. Kiviluoto,
E. Kivilaakso,
R. E. Burgeson,
P. Sipponen, and I. Virtanen.
1996.
Alpha 6 beta 4 integrin and newly deposited laminin-1 and laminin-5 form the adhesion mechanism of gastric carcinoma. Continuous expression of laminins but not that of collagen VII is preserved in invasive parts of the carcinomas: implications for acquisition of the invading phenotype.
Am. J. Pathol.
149:781-793[Abstract].
|
| 76.
|
Toker, A., and L. C. Cantley.
1997.
Signalling through the lipid products of phosphoinositide-3-OH kinase.
Nature
387:673-676[CrossRef][Medline].
|
| 77.
|
Turner, B. C.,
B. G. Haffty,
L. Narayanan,
J. Yuan,
P. A. Havre,
A. A. Gumbs,
L. Kaplan,
J. L. Burgaud,
D. Carter,
R. Baserga, and P. M. Glazer.
1997.
Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation.
Cancer Res.
57:3079-3083[Abstract/Free Full Text].
|
| 78.
|
Uddin, S.,
B. Majchrzak,
P. C. Wang,
S. Modi,
M. K. Khan,
E. N. Fish, and L. C. Platanias.
2000.
Interferon-dependent activation of the serine kinase PI 3'-kinase requires engagement of the IRS pathway but not the Stat pathway.
Biochem. Biophys. Res. Commun.
270:158-162[CrossRef][Medline].
|
| 79.
|
Unkeless, J. C., and J. Jin.
1997.
Inhibitory receptors, ITIM sequences and phosphatases.
Curr. Opin. Immunol.
9:338-343[CrossRef][Medline].
|
| 80.
|
Valverde, A. M.,
M. Lorenzo,
S. Pons,
M. F. White, and M. Benito.
1998.
Insulin receptor substrate (IRS) proteins IRS-1 and IRS-2 differential signaling in the insulin/insulin-like growth factor-I pathways in fetal brown adipocytes.
Mol. Endocrinol.
12:688-697[Abstract/Free Full Text].
|
| 81.
|
Vanderneut, R.,
P. Krimpenfort,
J. Calafat,
C. M. Niessen, and A. Sonnenberg.
1996.
Epithelial detachment due to absence of hemidesmosomes in integrin beta-4 null mice.
Nat. Genet.
13:366-369[CrossRef][Medline].
|
| 82.
|
van Waes, C.,
K. F. Kozarsky,
A. B. Warren,
L. Kidd,
D. Paugh,
M. Liebert, and T. E. Carey.
1991.
The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4.
Cancer Res.
51:2395-2402[Abstract/Free Full Text].
|
| 83.
|
Vuori, K., and E. Ruoslahti.
1994.
Association of insulin receptor substrate-1 with integrins.
Science
266:1576-1578[Abstract/Free Full Text].
|
| 84.
|
White, M. F.
1997.
The insulin signalling system and the IRS proteins.
Diabetologia
40(Suppl. 2):S2-S17.
|
| 85.
|
Withers, D. J.,
J. S. Gutierrez,
H. Towery,
D. J. Burks,
J. M. Ren,
S. Previs,
Y. Zhang,
D. Bernal,
S. Pons,
G. I. Shulman,
S. Bonner-Weir, and M. F. White.
1998.
Disruption of IRS-2 causes type 2 diabetes in mice.
Nature
391:900-904[CrossRef][Medline].
|
| 86.
|
Yamauchi, T.,
Y. Kaburagi,
K. Ueki,
Y. Tsuji,
G. R. Stark,
I. M. Kerr,
T. Tsushima,
Y. Akanuma,
I. Komuro,
K. Tobe,
Y. Yazaki, and T. Kadowaki.
1998.
Growth hormone and prolactin stimulate tyrosine phosphorylation of insulin receptor substrate-1, -2, and -3, their association with p85 phosphatidylinositol 3-kinase (PI3-kinase), and concomitantly PI3-kinase activation via JAK2 kinase.
J. Biol. Chem.
273:15719-15726[Abstract/Free Full Text].
|
Molecular and Cellular Biology, August 2001, p. 5082-5093, Vol. 21, No. 15
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.15.5082-5093.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kim, T. H., Kim, H. I., Soung, Y. H., Shaw, L. A., Chung, J.
(2009). Integrin ({alpha}6{beta}4) Signals Through Src to Increase Expression of S100A4, a Metastasis-Promoting Factor: Implications for Cancer Cell Invasion. Mol Cancer Res
7: 1605-1612
[Abstract]
[Full Text]
-
Al-Mahmood, S., Colin, S., Farhat, N., Thorin, E., Steverlynck, C., Chemtob, S.
(2009). Potent in Vivo Antiangiogenic Effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an Antisense Oligonucleotide Preventing the Expression of Insulin Receptor Substrate-1. J. Pharmacol. Exp. Ther.
329: 496-504
[Abstract]
[Full Text]
-
Hanke, S., Mann, M.
(2009). The Phosphotyrosine Interactome of the Insulin Receptor Family and Its Substrates IRS-1 and IRS-2. Mol. Cell. Proteomics
8: 519-534
[Abstract]
[Full Text]
-
Thorn, C C, Freeman, T C, Scott, N, Guillou, P J, Jayne, D G
(2009). Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut
58: 404-412
[Abstract]
[Full Text]
-
Gilcrease, M. Z., Kilpatrick, S. K., Woodward, W. A., Zhou, X., Nicolas, M. M., Corley, L. J., Fuller, G. N., Tucker, S. L., Diaz, L. K., Buchholz, T. A., Frost, J. A.
(2009). Coexpression of {alpha}6{beta}4 Integrin and Guanine Nucleotide Exchange Factor Net1 Identifies Node-Positive Breast Cancer Patients at High Risk for Distant Metastasis. Cancer Epidemiol. Biomarkers Prev.
18: 80-86
[Abstract]
[Full Text]
-
Szabolcs, M., Keniry, M., Simpson, L., Reid, L. J., Koujak, S., Schiff, S. C., Davidian, G., Licata, S., Gruvberger-Saal, S., Murty, V. V.V.S., Nandula, S., Efstratiadis, A., Kushner, J. A., White, M. F., Parsons, R.
(2009). Irs2 Inactivation Suppresses Tumor Progression in Pten+/- Mice. Am. J. Pathol.
174: 276-286
[Abstract]
[Full Text]
-
Dutta, U., Shaw, L. M.
(2008). A Key Tyrosine (Y1494) in the {beta}4 Integrin Regulates Multiple Signaling Pathways Important for Tumor Development and Progression. Cancer Res.
68: 8779-8787
[Abstract]
[Full Text]
-
Kim, H. I., Huang, H., Cheepala, S., Huang, S., Chung, J.
(2008). Curcumin Inhibition of Integrin ({alpha}6{beta}4)-Dependent Breast Cancer Cell Motility and Invasion. Cancer Prevention Research
1: 385-391
[Abstract]
[Full Text]
-
Folgiero, V., Bachelder, R. E., Bon, G., Sacchi, A., Falcioni, R., Mercurio, A. M.
(2007). The {alpha}6{beta}4 Integrin Can Regulate ErbB-3 Expression: Implications for {alpha}6{beta}4 Signaling and Function. Cancer Res.
67: 1645-1652
[Abstract]
[Full Text]
-
Bertotti, A., Comoglio, P. M., Trusolino, L.
(2006). {beta}4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. JCB
175: 993-1003
[Abstract]
[Full Text]
-
Dearth, R. K., Cui, X., Kim, H.-J., Kuiatse, I., Lawrence, N. A., Zhang, X., Divisova, J., Britton, O. L., Mohsin, S., Allred, D. C., Hadsell, D. L., Lee, A. V.
(2006). Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2. Mol. Cell. Biol.
26: 9302-9314
[Abstract]
[Full Text]
-
Ma, Z., Gibson, S. L., Byrne, M. A., Zhang, J., White, M. F., Shaw, L. M.
(2006). Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis. Mol. Cell. Biol.
26: 9338-9351
[Abstract]
[Full Text]
-
Pullar, C. E., Baier, B. S., Kariya, Y., Russell, A. J., Horst, B. A.J., Marinkovich, M. P., Isseroff, R. R.
(2006). beta4 Integrin and Epidermal Growth Factor Coordinately Regulate Electric Field-mediated Directional Migration via Rac1. Mol. Biol. Cell
17: 4925-4935
[Abstract]
[Full Text]
-
Cui, X., Kim, H.-J., Kuiatse, I., Kim, H., Brown, P. H., Lee, A. V.
(2006). Epidermal Growth Factor Induces Insulin Receptor Substrate-2 in Breast Cancer Cells via c-Jun NH2-Terminal Kinase/Activator Protein-1 Signaling to Regulate Cell Migration.. Cancer Res.
66: 5304-5313
[Abstract]
[Full Text]
-
Kalfa, N., Ecochard, A., Patte, C., Duvillard, P., Audran, F., Pienkowski, C., Thibaud, E., Brauner, R., Lecointre, C., Plantaz, D., Guedj, A.-M., Paris, F., Baldet, P., Lumbroso, S., Sultan, C.
(2006). Activating Mutations of the Stimulatory G Protein in Juvenile Ovarian Granulosa Cell Tumors: A New Prognostic Factor?. J. Clin. Endocrinol. Metab.
91: 1842-1847
[Abstract]
[Full Text]
-
Wilhelmsen, K., Litjens, S. H.M., Sonnenberg, A.
(2006). Multiple Functions of the Integrin {alpha}6{beta}4 in Epidermal Homeostasis and Tumorigenesis. Mol. Cell. Biol.
26: 2877-2886
[Full Text]
-
Fukumoto, S., Miner, J. H., Ida, H., Fukumoto, E., Yuasa, K., Miyazaki, H., Hoffman, M. P., Yamada, Y.
(2006). Laminin {alpha}5 Is Required for Dental Epithelium Growth and Polarity and the Development of Tooth Bud and Shape. J. Biol. Chem.
281: 5008-5016
[Abstract]
[Full Text]
-
Bertotti, A., Comoglio, P. M., Trusolino, L.
(2005). {beta}4 Integrin Is a Transforming Molecule that Unleashes Met Tyrosine Kinase Tumorigenesis. Cancer Res.
65: 10674-10679
[Abstract]
[Full Text]
-
Berdugo, M., Andrieu-Soler, C., Doat, M., Courtois, Y., BenEzra, D., Behar-Cohen, F.
(2005). Downregulation of IRS-1 Expression Causes Inhibition of Corneal Angiogenesis. IOVS
46: 4072-4078
[Abstract]
[Full Text]
-
Vulin, A. I., Jacob, K. K., Stanley, F. M.
(2005). Integrin Activates Receptor-Like Protein Tyrosine Phosphatase {alpha}, Src, and Rho to Increase Prolactin Gene Expression through a Final Phosphatidylinositol 3-Kinase/Cytoskeletal Pathway that Is Additive with Insulin. Endocrinology
146: 3535-3546
[Abstract]
[Full Text]
-
Nikolopoulos, S. N., Blaikie, P., Yoshioka, T., Guo, W., Puri, C., Tacchetti, C., Giancotti, F. G.
(2005). Targeted Deletion of the Integrin {beta}4 Signaling Domain Suppresses Laminin-5-Dependent Nuclear Entry of Mitogen-Activated Protein Kinases and NF-{kappa}B, Causing Defects in Epidermal Growth and Migration. Mol. Cell. Biol.
25: 6090-6102
[Abstract]
[Full Text]
-
Raymond, K., Kreft, M., Janssen, H., Calafat, J., Sonnenberg, A.
(2005). Keratinocytes display normal proliferation, survival and differentiation in conditional {beta}4-integrin knockout mice. J. Cell Sci.
118: 1045-1060
[Abstract]
[Full Text]
-
Nagle, J. A., Ma, Z., Byrne, M. A., White, M. F., Shaw, L. M.
(2004). Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis. Mol. Cell. Biol.
24: 9726-9735
[Abstract]
[Full Text]
-
Chung, J., Yoon, S.-O., Lipscomb, E. A., Mercurio, A. M.
(2004). The Met Receptor and {alpha}6{beta}4 Integrin Can Function Independently to Promote Carcinoma Invasion. J. Biol. Chem.
279: 32287-32293
[Abstract]
[Full Text]
-
Neid, M., Datta, K., Stephan, S., Khanna, I., Pal, S., Shaw, L., White, M., Mukhopadhyay, D.
(2004). Role of Insulin Receptor Substrates and Protein Kinase C-{zeta} in Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Pancreatic Cancer Cells. J. Biol. Chem.
279: 3941-3948
[Abstract]
[Full Text]
-
Diaz, L. K., Zhou, X., Welch, K., Sahin, A., Gilcrease, M. Z.
(2004). Chromogenic In Situ Hybridization for {alpha}6{beta}4 Integrin in Breast Cancer: Correlation with Protein Expression. J. Mol. Diagn.
6: 10-15
[Abstract]
[Full Text]
-
Owens, D. M., Romero, M. R., Gardner, C., Watt, F. M.
(2003). Suprabasal {alpha}6{beta}4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGF{beta} signalling. J. Cell Sci.
116: 3783-3791
[Abstract]
[Full Text]
-
Lee, A. V., Schiff, R., Cui, X., Sachdev, D., Yee, D., Gilmore, A. P., Streuli, C. H., Oesterreich, S., Hadsell, D. L.
(2003). New Mechanisms of Signal Transduction Inhibitor Action: Receptor Tyrosine Kinase Down-Regulation and Blockade of Signal Transactivation. Clin. Cancer Res.
9: 516s-523s
[Abstract]
[Full Text]
-
Geuijen, C. A. W., Sonnenberg, A.
(2002). Dynamics of the alpha 6beta 4 Integrin in Keratinocytes. Mol. Biol. Cell
13: 3845-3858
[Abstract]
[Full Text]
-
Chung, J., Bachelder, R. E., Lipscomb, E. A., Shaw, L. M., Mercurio, A. M.
(2002). Integrin ({alpha}6{beta}4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. JCB
158: 165-174
[Abstract]
[Full Text]
-
Morena, A., Riccioni, S., Marchetti, A., Polcini, A. T., Mercurio, A. M., Blandino, G., Sacchi, A., Falcioni, R.
(2002). Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells. Blood
100: 96-106
[Abstract]
[Full Text]
-
Mariotti, A., Kedeshian, P. A., Dans, M., Curatola, A. M., Gagnoux-Palacios, L., Giancotti, F. G.
(2001). EGF-R signaling through Fyn kinase disrupts the function of integrin {alpha}6{beta}4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. JCB
155: 447-458
[Abstract]
[Full Text]